Summary Fifteen human glioma cell lines were examined for their sensitivity to 1 ,3-bis(chloroethyl)-nitrosourea (BCNU, carmustine) and cisdichlorodiamminoplatinum (cisplatin), the induction of DNA interstrand cross-linking (DNA-ISC) induced by the two agents and cellular 06_ alkylguanine alkyltransferase (ATase) activity. Cell lines differed in their sensitivities to BCNU by up to 12-fold and to cisplatin by up to 21 -fold. For both drugs, the extent of DNA-ISC was related to the drug sensitivity. There was a wide range of cellular ATase levels. Increasing ATase levels correlated with increased resistance to BCNU and with decreased formation of DNA-ISC following treatment with BCNU. In contrast, following treatment with cisplatin, there was no correlation between cellular ATase content and cytotoxicity or between ATase and DNA-ISC. Four sublines of varying ATase activity were prepared from one of the cell lines. These sublines showed a sensitivity to BCNU in inverse proportion to ATase activity, while sensitivity to cisplatin was more uniform. The experiments confirm the direct relationship between ATase concentration and sensitivity to BCNU in glioma cells. Although there was some correlation between cisplatin cytotoxicity and BCNU cytotoxicity, this was not mediated through ATase.
The treatment for high-grade gliomas remains relatively ineffective. Chloroethylnitrosoureas (CNUs) are among the most effective cytotoxic agents used, but only 30% of tumours show a response, and this is usually short lived (Fine et al, 1993) . It has generally been accepted that the formation of cross-links between complementary strands of duplex DNA represents the crucial mechanism for the cytotoxic, anti-tumour activity of CNUs. The exact details of the mechanism of cross-link formation are not entirely clear. Initial evidence suggested that the DNA-ISC was produced via an initial alkylation at the guanine 06 position followed by a link to a cytosine on the opposite strand (Kohn, 1977; Erickson et al, 1980; Tong et al; 1982) because cell lines defective in repair of 06-methylguanine were hypersensitive to both the cytotoxic and the DNA cross-linking effects of CNUs. However, the only di-adduct identified that might represent the cross-link structure in CNU-treated duplex DNA did not involve the 06 position of guanine. It was then proposed that an initial alkylation by a chloroethyl ion at 06-guanine is followed by intramolecular rearrangement via 06, N'-ethanoguanine to yield the observed N3-cytosine, N'-guanine ethane cross-link (Tong et al, 1982; Gonzaga et al, 1989) . It is generally accepted that ATase, a DNA repair protein, causes resistance to CNUs by removing the chloroethyl groups from the guanine 06 position and preventing the formation of the DNA-ISC (Robins et al, 1983; Brent, 1984) . Cell lines resistant to CNUs generally have a low level of DNAISCs and a high level of ATase. In contrast, cisplatin, which also shows activity in glioma treatment, causes intrastrand cross-links and DNA-ISC through guanine N7 positions, and these lesions are not repaired by ATase (Lippert, 1981; Eastman, 1982) . Previous studies of the mechanism of cytotoxicity of cisplatin and CNUs in a variety of human and rodent cell lines have given conflicting results, with some showing correlation between DNA-ISC production by both CNUs and cisplatin (Sariban et al, 1987) and others showing no correlation between either cytotoxicity or DNA-ISC induced by the two agents (Laurent et al, 1981; Bodell et al, 1985; Aida et al, 1987) . A correlation between the two drugs may be related to DNA repair mechanisms other than ATase. The relationship between ATase, CNU cytotoxicity and DNA damage induced by CNUs has not been assessed in human glioma cell lines and compared directly with the action of a cytotoxic agent in which repair of the DNA-drug adduct is not mediated by ATase. There therefore remains some uncertainty about the degree to which ATase activity is responsible for sensitivity of glioma cells to CNUs. The current study was undertaken to further define this relationship.
MATERIALS AND METHODS
Cell cultures were established from biopsy specimens of grade III and IV gliomas. One line was multiply passaged (passages 569-576) and 14 were early passage (passages 4-20). Four additional cell lines were prepared from a single line (SB) by plating one cell per well in a 96-well plate. Twenty cell lines were cultured Cytotoxicity assay Drug-induced cytotoxicity was analysed using the sulphorhodamine B assay (SRB) (Rubinstein et al, 1990 Excess radioactivity was removed by washing, and the cultures were grown for an additional 12-24 h to allow for the incorporation of labelled DNA into high molecular weight DNA. Cells were exposed to drug for 2 h and then washed with fresh medium. The cells were incubated in the absence of drug for 6 h to allow for the formation of DNA-ISC. The cells were irradiated at 0°C with 4.5 gray (Gy) at a dose rate of 4.5 Gy min-'. The elution procedure used was essentially that described previously by Kohn (1981) . The cross-link index (CLI) was calculated after 12 h elution using the formula CLI=(Il-RO)/(1-R )-1 where Ro and R1 are the relative retention for untreated and treated cells respectively (Ewig et al, 1978) . Some cell lines had a significant number of drug-induced single-strand breaks and therefore new R, values were corrected (Kohn, 1981 Figure 3A ) and decreasing DNA-ISC ( Figure 3C ), following treatment with BCNU. In contrast, the sublines all remained relatively sensitive to treatment with cisplatin ( Figure 3B) , and all had a high level of DNA-ISC ( Figure 3D ). (Robins et al, 1983; Brent, 1984; Bodell et al, 1986; Ludlum et al, 1986) . One cell line (478) did not conform to this distribution, and there is no explanation for this observation. This cell line also had a level of DNA-ISC induced by cisplatin out of proportion to its sensitivity and thus may lack a different DNA repair mechanism, thereby possessing an alternative mechanism of drug resistance. This study has more precisely established the relationship of ATase level to CNU and another DNA-binding drug, cisplatin.
There was no significant correlation observed for ATase in relation to cytotoxicity or DNA-interstrand cross-links induced by cisplatin; this was not expected as cisplatin forms DNA interstrand cross-links through the N7 position of guanine (Eastman, 1982) . (Sariban et al, 1987 (Laurent et al, 1981) . Another study investigated four rat brain tumour cell lines and found that resistance to BCNU was associated with decreased cross-link formation. In these cell lines, cytotoxicity and the number of DNA cross-links formed after treatment with cisplatin were similar. The cell lines used in this experiment were cultured after exposure to CNUs and thus may have selected out cells with resistant mechanisms specific for CNUs, similar to the sublines in our study (Bodell et al, 1985) . Indirect evidence that showed that N-methyl-N'-nitro-N-nitrosoguanidine pretreatment before cisplatin did not increase cytotoxicity or DNA-ISC led the authors to conclude that there was no cross-resistance between CNUs and cisplatin; however, they did not compare the relative sensitivities and ability to induce DNA-ISC of the two agents (Gibson et al, 1985) . In support of our study, it has been shown that novobicin pretreatment to inhibit topoisomerase II activity has decreased the rate of repair of both cisplatin-and BCNU-induced DNA interstrand cross-links, with a corresponding increase in cytotoxicity. This implies that a DNA repair mechanism is involved in resistance to both these agents (Ali-Osman et al, 1993) . More recently, a report of preliminary data showing response to cisplatin and cyclophosphamide in patients with ovarian carcinoma showed correlation with a low ATase level (Chen et al, 1994) . This association, together with our results, suggests that there may be an additional resistance mechanism associated with ATase expression which confers resistance to cisplatin.
Although the relationship between resistance to BCNU and cellular activity of ATase has been shown previously, there was still uncertainty as to how important ATase is as a mechanism of resistance. This study indicates that ATase is the major mechanism of resistance to BCNU in glioma cells. It has also demonstrated cross-resistance between BCNU and cisplatin that is not related to ATase, implying that there may be an additional and associated mechanism of resistance.
